RESEARCH TRIANGLE PARK, N.C., Oct. 6, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq: SNCE), an industry-leading Metasite™, announced today that it will Announced the awarding of stock awards. Inc. 2022 Employment Attraction Incentive Award Plan (the “Plan”). The plan was approved by Science 37’s Board of Directors in November 2022. Pursuant to Nasdaq Listing Rule 5635(c)(4), this award was approved by Science 37’s Compensation Committee and was made as a material solicitation for non-executive employee compensation. Commencement of employment with the Company.
In connection with the commencement of employment, on October 6, 2023, we will purchase an aggregate of 15,300 shares of Science 37’s common stock at an exercise price of $0.4085 per share, which is the closing sale price of Science 37’s common stock on Nasdaq Stock. options are given. Market LLC was granted three new employees on the date of grant.
The term of the option is 10 years with a vesting schedule of 4 years, with 25% of the shares underlying the option vesting in the first year of the grant date, and the remaining underlying shares vesting equally until fully vested. Rights vest in monthly installments. His 4th anniversary from the date of grant. Contingent on the applicable employee’s continued employment with Science 37 through each applicable vesting date.
About Science 37
Science 37 Holdings, Inc. (Nasdaq: SNCE)’s mission is to accelerate clinical research by making trials accessible to all patients. Through Metasite™, we reach expanded patient populations beyond our traditional facilities, further increasing patient diversity and realizing our goal of clinical research that works for everyone. Patients have the flexibility to participate from the comfort of their home, local health care provider, or traditional facility, as appropriate. Our Metasite leverages a unique technology platform with in-house medical and operational experts to drive uniform research orchestration, resulting in enhanced compliance and high quality data. For more information, visit www.science37.com or email science37@science37.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of federal securities laws, including statements regarding Science 37’s products and the markets in which it operates, and Science 37’s expected growth and profitability. It is. These forward-looking statements generally include “believe,” “could,” “could,” “seek,” “anticipate,” “expect,” “anticipate,” “estimate,” “intend” “will”, “strategy”, “future”, “opportunity”, “plan”, “may”, “might”, “should”, “would”, “will”, “will” Expressions such as “will continue”, “will probably continue”, and “maybe there will be consequences”. Forward-looking statements are predictions, forecasts or other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to: (i) the ability to maintain the listing of Science 37’s securities on Nasdaq Stock Market LLC; (ii) changes in the competitive and highly regulated industry in which Science 37 operates; fluctuations in performance among its competitors; Science 37; fluctuations in the price of Science 37’s securities due to a variety of factors, including changes in laws and regulations affecting 37’s business and changes in capitalization; (iii) the ability of Science 37 to implement its business plans, forecasts and other expectations; the ability of Science 37 to identify and realize opportunities, (iv) the risk that Science 37 may never achieve or maintain profitability, and (v) the need for Science 37 to raise additional capital to execute its business plans. (vi) risks that anticipated cost savings may not be realized; and (vii) risks related to general economic and financial market conditions. The foregoing list of factors is not exhaustive. Securities and Exchange Commission (the “SEC”) on March 6, 2023, and in other documents that Science 37 files from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events or results to differ materially from those contained in the forward-looking statements. . Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Science 37 is cautioned not to place undue reliance on forward-looking statements, whether as a result of new information, future events or otherwise; We undertake no obligation, and do not intend, to update or revise these forward-looking statements. Required by law. Science 37 gives no guarantee that Science 37 will achieve your expectations.
Media inquiries:
Grazia Molen
science 37
PR@science37.com
Public relations activities for investors:
steve halper
Life science advisor
investors@science37.com
![](https://s.yimg.com/ny/api/res/1.2/Bk4GIFruQ5sZUQRpw5U6JA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MA--/https://ml.globenewswire.com/media/MTMxNzExOTQtMWM2YS00ZjBjLWExNzMtOGUxYWE4NDZjZGQxLTEyMzM1Nzk=/tiny/Science-37-Inc-.png)